Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Cadrenal Therapeutics Inc (CVKD)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.00-5.66%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CVKD yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Stabilize executive leadership after CFO and CEO transitions | The company is focused on stabilizing leadership after CFO changes. | Intact | Interim leadership persists beyond 2 quarters or further executive departures | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not an established earnings compounder. The thesis is in a watch state, with low confidence, loss-making results, and volatile management execution.
The evidence does not provide a valuation measure or specific market expectations, so whether the shares are cheap, fair, or expensive versus peers cannot be assessed. The recent earnings miss and weak financial performance are known concerns, but the snapshot does not show how fully they are reflected in expectations.
Over the multi-year view, progress depends on advancing CAD-1005 toward a Phase 3 trial and developing tecarfarin, while management pursues partnerships and licensing. These priorities have mixed implementation status and no direct financial metrics disclosed; near term, weak results, restructuring, and elevated earnings-miss risk remain important concerns.
A favorable path depends on translating trial and regulatory progress into partnerships or other measurable business progress. The thesis could weaken if execution stalls or financial results remain weak; broader Healthcare sentiment may also shift with sector bellwethers and economic conditions.
For the next one to three years, CVKD remains a low-confidence, high-risk clinical development story rather than a proven business, with the thesis hinging on execution and evidence of progress. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Cadrenal Therapeutics Inc's published investment case. The stated target is No further dilutive warrant issuances in next 4 quarters. |
| Intact |
| New dilutive warrant issuances or adverse capital structure changes |
Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce operating losses and improve cash flow | Cadrenal is improving its losses and cash flow, with operating losses shrinking from $3.93M to $2.51M. | Intact | Operating income worse than negative $2.5M next 4 quarters | Operating income: $-3.34M FY2026-Q2; GAAP. Published target: Operating income better than negative $2.5M next 4 quarters. Target period is not explicitly aligned with this observation. Aug 13, 2026-3,340,400 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Total operating expenses were $3.3 million compared to $3.7 million for the same period in 2025.” “Based on its current operating plan, the Company believes these resources are expected to fund operations through the first quarter of 2027.” Operating income was $-3.340 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-3.01 → $-3.01 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-3.01 | $6,300,000 | 1 / 2 |
| 2026-07-25 | $-3.01 | $6,300,000 | 1 / 2 |
| 2026-07-26 | $-3.01 | $6,300,000 | 1 / 2 |
| 2026-07-27 | $-3.09 | $0 | 1 / 2 |
| 2026-07-28 | $-3.09 | $0 | 1 / 2 |
| 2026-07-29 | $-3.01 | $6,300,000 | 1 / 2 |
| 2026-07-30 | $-3.01 | $6,300,000 | 1 / 2 |
| 2026-07-31 | $-3.01 | $6,300,000 | 1 / 2 |
| 2026-08-01 | $-3.01 | $6,300,000 | 1 / 2 |
| 2026-08-02 | $-3.09 | $0 | 1 / 2 |
| 2026-08-03 | $-3.01 | $6,300,000 | 1 / 2 |
| 2026-08-04 | $-3.09 | $0 | 1 / 2 |
| 2026-08-05 | $-3.01 | $6,300,000 | 1 / 2 |
| 2026-08-06 | $-3.01 | $6,300,000 | 1 / 2 |
| 2026-08-07 | $-3.01 | $6,300,000 | 1 / 2 |
| 2026-08-08 | $-3.09 | $0 | 1 / 2 |
| 2026-08-09 | $-3.09 | $0 | 1 / 2 |
| 2026-08-10 | $-3.01 | $6,300,000 | 1 / 2 |
| 2026-08-11 | $-3.01 | $6,300,000 | 1 / 2 |
| 2026-08-12 | $-3.09 | $0 | 1 / 2 |
| 2026-08-13 | $-3.01 | $6,300,000 | 1 / 2 |
| 2026-08-14 | $-3.01 | $6,300,000 | 1 / 2 |
| 2026-08-15 | $-3.01 | $6,300,000 | 1 / 2 |
| 2026-08-16 | $-3.01 | $6,300,000 | 1 / 2 |
| 2026-08-17 | $-3.01 | $6,300,000 | 1 / 2 |
| 2026-08-18 | $-3.01 | $6,300,000 | 2 / 2 |
| 2026-08-19 | $-3.01 | $6,300,000 | 2 / 2 |
| 2026-08-20 | $-3.25 | $6,300,000 | 2 / 3 |
| 2026-08-21 | $-3.25 | $6,300,000 | 2 / 3 |
| 2026-08-22 | $-3.25 | $6,300,000 | 2 / 3 |
| 2026-08-23 | $-3.25 | $6,300,000 | 2 / 3 |
| 2026-08-24 | $-3.25 | $6,300,000 | 2 / 3 |
| 2026-08-25 | $-3.25 | $6,300,000 | 2 / 3 |
| 2026-08-26 | $-3.25 | $6,300,000 | 2 / 3 |
| 2026-08-27 | $-3.25 | $6,300,000 | 2 / 3 |
| 2026-08-28 | $-3.25 | $6,300,000 | 2 / 3 |
| 2026-08-29 | $-3.25 | $6,300,000 | 2 / 3 |
| 2026-08-30 | $-3.25 | $6,300,000 | 2 / 3 |
| 2026-08-31 | $-3.25 | $6,300,000 | 2 / 3 |
| 2026-09-01 | $-3.25 | $6,300,000 | 2 / 3 |
| 2026-09-02 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-03 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-04 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-05 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-06 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-07 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-08 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-09 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-10 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-11 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-12 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-13 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-14 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-15 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-16 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-17 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-18 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-19 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-20 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-21 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-22 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-23 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-24 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-25 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-26 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-27 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-28 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-29 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-09-30 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-01 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-02 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-03 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-04 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-05 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-06 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-07 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-08 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-09 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-10 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-11 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-12 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-13 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-14 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-15 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-16 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-17 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-18 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-19 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-20 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-21 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-22 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-23 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-24 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-25 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-26 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-27 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-28 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-29 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-30 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-10-31 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-11-01 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-11-02 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-11-03 | $-3.01 | $6,300,000 | 2 / 3 |
| 2026-11-04 | $-3.01 | $6,300,000 | 2 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.